Less than two weeks after the Food and Drug Administration (FDA) announced it had launched an investigation into reports of burns and potential permanent scarring related to the Zecuity patch used to treat migraine headaches, the manufacturer, Teva Pharmaceuticals, announced it has decided to temporarily suspend sales, marketing and distribution to launch its own investigation into related safety risks. The FDA is informing health care professionals to discontinue prescribing Zecuity, and informing patients to stop using any remaining patches and contact their prescribers for an alternative migraine medicine. The Zecuity patch contains the active ingredient sumatriptan, a prescription medication used ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.